← Back

Spruce Biosciences

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. Their lead product candidate, Tildacerfont, has the potential to be the first FDA-approved therapy for congenital adrenal hyperplasia (CAH), a rare endocrine disease where patients are unable to make normal levels of steroid in their body. The company is currently conducting Ph II clinical trials.

LocationSan Francisco, CA
CEORichard King
Partner Bali Muralidhar
Websitewww.sprucebiosciences.com